Pancreatic Cancer Therapy by MHI's "vero4DRT" Radiation Therapy System World's First Application of Dynamic Tracking with IMRT Monitored in Real Time Tokyo, July 30, 2013 - (JCN Newswire) - The "vero4DRT," a radiation therapy system featuring tracking irradiation capability-marketed as the "MHI-TM2000 Linear Accelerator"-that was earlier delivered to Kyoto University Hospital, has now entered into service for dynamic tracking with intensity-modulated radiation therapy (IMRT) for pancreatic cancer. The system integrates two advanced treatment methods: 1) a dynamic tracking function that tracks a respiratorily moving carcinomatous lesion in real time, and continuously irradiates the targeted lesion with pinpoint accuracy; and 2) IMRT, which is one of the newest irradiation techniques in radiotherapy. The inauguration of the new vero4DRT system at Kyoto University Hospital marks a world first in the application of dynamic tracking with IMRT through real-time monitoring. Radiation therapy for cancer today is moving forward in pursuit of sufficient irradiation of the carcinomatous lesion and minimal radiation effect on nearby internal organs, normal tissue and organs at risk. IMRT is an innovative therapy method that achieves focused irradiation doses into such lesions. It incorporates the newest irradiation technique whereby dose intensity distribution at the irradiation target is modulated and irradiation is performed from multiple directions, enabling the formation of a high-dose area corresponding precisely to the complex shape of the carcinomatous lesion and reduction in the dose irradiated to normal organs. IMRT is already contributing to improved results in the treatment of numerous cancers such as prostate cancer and head and neck cancers. But with lesions in internal organs such as the lungs, liver or pancreas that move along with the patient's respiration, treatments involving use of highly accurate irradiation techniques such as IMRT were not easy to perform until now. The vero4DRT is today's most advanced radiation therapy system. By integrating MHI's image processing technologies with its high-precision irradiation technologies, the vero4DRT can perform highly accurate target-tracking irradiation monitored in real time, even with lesions that move due to respiration, etc. The integration of dynamic-tracking therapy and IMRT has now enabled patients of pancreatic cancer, whose lesions move by respiration, to be treated with minimal stress by breathing normally even during treatment. Besides minimizing potential side-effects on healthy tissue, the system thus reduces the burdens on both the patient and the attending medical staff. This research was conducted with support from the "Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program)", which is instituted by the Council for Science and Technology Policy (CSTP), through the Japan Society for the Promotion of Science (JSPS). Support in medical aspects was provided by Kyoto University and the Institute of Biomedical Research and Innovation. In developing the vero4DRT system, MHI was supported by the New Energy and Industrial Technology Development Organization (NEDO). Full-scale entry into the medical equipment field began with acquisition of pharmaceutical approval for the system in January 2008. Sales activities in both the domestic and global markets got under way in 2010 after receiving authorization to manufacture and market the vero4DRT as a system equipped with a tracking-irradiation feature. Going forward, as the system is expected to come into wider usage for even more advanced therapies, an increasing number of institutions are expected to adopt it, and MHI intends to respond with even more proactive sales expansion activities. About Mitsubishi Heavy Industries Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, Japan, is one of the world's leading heavy machinery manufacturers, with consolidated sales of 2,820.9 billion for the year ended March 31, 2012. MHI's diverse lineup of products and services encompasses shipbuilding, power plants, chemical plants, environmental equipment, steel structures, industrial and general machinery, aircraft, space rocketry and air-conditioning systems. For more information, please visit the MHI website at www.mhi.co.jp. Contact: Mitsubishi Heavy Industries Hideo Ikuno email@example.com +81-3-6716-5277 Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net Provider ID: 00027149
Pancreatic Cancer Therapy by MHI's "vero4DRT" Radiation Therapy
Press spacebar to pause and continue. Press esc to stop.